Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Neoadjuvant Anti-PD-L1 Immunotherapy for the Treatment of Advanced Melanoma

Trial Status: active

This phase II trial tests the safety and effectiveness of neoadjuvant ant-PD-L1 immunotherapy nivolumab, nivolumab/relatlimab-rmbw, and ipilimumab in treating patients with melanoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) based on the tumor biomarker, PD-L1. PD-L1 is a protein on tumor cells that stops the immune system from attacking the cancer. Neoadjuvant immunotherapy is treatment given before surgery. Neoadjuvant immunotherapy with monoclonal antibodies, such as nivolumab, nivolumab/relatlimab-rmbw, and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may allow researchers to find out if neoadjuvant immunotherapy treatment based on tumor biomarkers results in better patient outcomes.